---
schema_version: "secwatch.filing_event.v1"
accession: "0001640334-26-000475"
form_type: "8-K"
ticker: "ARTL"
cik: "0001621221"
company_name: "ARTELO BIOSCIENCES, INC."
filed_at: "2026-03-18T23:59:59+00:00"
generated_at: "2026-05-15T09:52:45.086914+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Artelo Biosciences raises $310k via 12% bridge notes with default conversion feature

## Summary
- Issued two 12% bridge notes totaling $350,300 principal ($237,300 Vanquish + $113,000 Boot) for net proceeds of $310,000 after $40,300 OID.
- Notes mature Jan 15, 2027; company may prepay at any time with no penalty.
- Upon default, notes can convert into common shares at the higher of $0.125 or 75% of the 10-day VWAP; conversion capped at 4.99% beneficial ownership per holder.
- Proceeds used for general working capital; Company reimbursed Vanquish $10,000 in fees.
- Securities issued under Regulation D, Section 4(a)(2); represented as accredited investors only.

## SEC filing metadata
- accession: 0001640334-26-000475
- form_type: 8-K
- ticker: ARTL
- cik: 0001621221
- company_name: ARTELO BIOSCIENCES, INC.
- filed_at: 2026-03-18T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1621221/000164033426000475/0001640334-26-000475-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1621221/000164033426000475/artl_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001640334-26-000475
- JSON: https://secwatch.observer/filing/0001640334-26-000475.json
- Plain text: https://secwatch.observer/filing/0001640334-26-000475.txt

## Key facts
- Material Agreements
  ARTELO BIOSCIENCES, INC. entered into Vanquish Purchase Agreement with Vanquish Funding Group Inc. valued at $210,000.00 (effective 2026-03-12).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: Vanquish Funding Group Inc.
  - Value: $210,000.00
  - Effective: 2026-03-12
  source text: On March 12, 2026, Artelo Biosciences, Inc. (the “Company”) entered into a Securities Purchase Agreement, dated as of March 12, 2026 (the “Vanquish Purchase Agreement”), with Vanquish Funding Group Inc., a Virginia corporation (“Vanquish”), pursuant to which the Company issued a 12% bridge note in the aggregate principal amount of $237,300.00, which includes an original issue discount of $27,300.00, for an aggregate purchase price of $210,000.00 (the “Vanquish Note”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1621221/000164033426000475/0001640334-26-000475-index.htm
- Material Agreements
  ARTELO BIOSCIENCES, INC. entered into Boot Purchase Agreement with Boot Capital LLC valued at $100,000.00 (effective 2026-03-12).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: Boot Capital LLC
  - Value: $100,000.00
  - Effective: 2026-03-12
  source text: Additionally, on March 12, 2026, the Company entered into a Securities Purchase Agreement, dated as of March 12, 2026 (the “Boot Purchase Agreement” and together with the Vanquish Purchase Agreement, the “Purchase Agreements”), with Boot Capital LLC, a Delaware limited liability company (“Boot” and together with Vanquish , the “Buyers”), pursuant to which the Company issued a 12% bridge note in the aggregate principal amount of $113,000.00, which includes an original issue discount of $13,000.00, for an aggregate purchase price of $100,000.00 (the “Boot Note” and together with the Vanquish Note, the “Notes”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1621221/000164033426000475/0001640334-26-000475-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.